Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001926193 | SCV002191747 | uncertain significance | Renal cell carcinoma | 2022-05-29 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 1422640). This variant has not been reported in the literature in individuals affected with MET-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces histidine, which is basic and polar, with asparagine, which is neutral and polar, at codon 748 of the MET protein (p.His748Asn). |
Ambry Genetics | RCV004945807 | SCV005450836 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-10-24 | criteria provided, single submitter | clinical testing | The p.H748N variant (also known as c.2242C>A), located in coding exon 8 of the MET gene, results from a C to A substitution at nucleotide position 2242. The histidine at codon 748 is replaced by asparagine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |